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Background: The highly selective α2-adrenoreceptor agonist,
dexmedetomidine, exerts neuroprotective, analgesic, anti-
inflammatory and sympatholytic properties that may be benefi-
cial for perinatal asphyxia. The optimal safe dose for pre-clinical
newborn neuroprotection studies is unknown.
Methods: Following cerebral hypoxia-ischaemia, dexmedeto-
midine was administered to nine newborn piglets in a
de-escalation dose study in combination with hypothermia
(whole body cooling to 33.5°C). Dexmedetomidine was adminis-
teredwith a loading dose of 1 μg/kg andmaintenance infusion at
doses from 10 to 0.6 μg/kg/h. One additional piglet was not
subjected to hypoxia-ischaemia. Blood for pharmacokinetic
analysis was sampled pre-insult and frequently post-insult. A
one-compartment linear disposition model was used to fit data.
Population parameter estimates were obtained using non-linear
mixed effects modelling.
Results: All dexmedetomidine infusion regimens led to
plasma concentrations above those associated with sedation in
neonates and children (0.4–0.8 μg/l). Seven out of the nine
piglets with hypoxia-ischaemia experienced periods of brady-
cardia, hypotension, hypertension and cardiac arrest; all
haemodynamic adverse events occurred in piglets with plasma
concentrations greater than 1 μg/l. Dexmedetomidine clearance
was 0.126 l/kg/h [coefficient of variation (CV) 46.6.%] and
volume of distribution was 3.37 l/kg (CV 191%).
Dexmedetomidine clearance was reduced by 32.7% at a tem-
perature of 33.5°C. Dexmedetomidine clearance was reduced by
55.8% following hypoxia-ischaemia.
Conclusions: Dexmedetomidine clearance was reduced
almost tenfold comparedwith adult values in the newborn piglet
following hypoxic-ischaemic brain injury and subsequent thera-
peutic hypothermia. Reduced clearance was related to cumula-
tive effects of both hypothermia and exposure to hypoxia. High
plasma levels of dexmedetomidine were associated with major
cardiovascular complications.
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Neonatal encephalopathy consequent on peri-natal hypoxia-ischaemia occurs in 1–3/1000
term births in the developed world and frequently
leads to serious and tragic consequences that devas-
tate lives and families, with huge financial burdens
for society.1 Although the recent introduction of
cooling represents a significant advance, despite
treatment around 40% survive with adverse
neurodevelopmental function.2 There is an unmet
need for novel, safe and effective therapies to opti-
mise brain protection following brain injury around
birth. Pre-clinical3 and clinical studies4 have empha-
sised the importance of sedation to realise the full
benefit of therapeutic hypothermia. There is also
increasing evidence that infection/inflammation
plays a part in the pathogenesis of neonatal encepha-
lopathy inbothhigh- and low-income socioeconomic
groups.5 A sedative that enhances macrophage
phagocytosis and bacterial clearance, minimising
inflammation-induced brain injury would be par-
ticularly useful in these patients.
Dexmedetomidine is a highly selective α2-
adrenoreceptor agonist that confers sedative,
anti-inflammatory, analgesic, sympatholytic and
organ-protective properties.6 Many of these proper-
ties, including sedation, are transduced via α2-
adrenoreceptor signalling,7 although imidazoline
receptor signalling may also contribute to the
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cardiovascular and organ-protective properties.8
Dexmedetomidine has extensive experimental
support for its neuroprotective effects via both α2-
and non-α2-adrenoceptor-mediated mechanisms of
action9–12 and has shownneuroprotection in neonatal
models of hypoxic-ischemic brain injury13 and anaes-
thetic brain injury in rodents.14–16 Dexmedetomidine
has superior anti-inflammatory effects compared
with other sedative drugs and may protect against
sepsis-induced brain and other organ injury.17,18
During therapeutic hypothermia (core body
cooling to 33.5°C for 72 h within 6 h of birth) in
ventilated infants with moderate to severe neonatal
encephalopathy, the current practice in most neona-
tal intensive care units includes sedation with a
morphine infusion to minimise discomfort.19 In
rodent studies, however, opioids have been seen to
augment hypoxic-ischaemic neuronal damage20
in contrast to dexmedetomidine, which was
neuroprotective.9,13 Dexmedetomidine use has been
described in premature neonates21,22 term neo-
nates23,24 and infants.24,25 Dexmedetomidine may be
associated with dose-dependent cardiovascular
effects in children; such effects may be opposing
and depend on central or peripheral actions.25–27
Specifically, bradycardia, hypotension and hyper-
tension may occur to varying degrees depending on
the plasma concentration.28 Therefore, close moni-
toring of circulatory dynamics and careful dose
titration of dexmedetomidine has been recom-
mended; this is particularly important under
hypothermic conditions where there is potential for
altered drug pharmacokinetics and pharmacody-
namics.29 Specific studies in the newborn are also
vital because dexmedetomidine clearance has been
reported to be one third that described in adults,
rapidly increasing to 85% of the adult value by 1
year of age.23
Pharmacokinetic (PK) studies are therefore
needed prior to pre-clinical neonatal studies of
dexmedetomidine neuroprotection with hypother-
mia. The aim of this study was to investigate the
influence of hypothermia and hypoxia-ischaemia on
dexmedetomidine pharmacokinetics in a piglet
perinatal asphyxia model.
Methods
Anaesthesia and surgical preparation
All animal experiments were performed under UK
Home Office Guidelines [Animals (Scientific proce-
dures) Act, 1986]. Ten male piglets aged less than
24 h, with a weight range of 1.6–2.0 kg were anaes-
thetised and surgically prepared as described previ-
ously.30 Briefly, piglets were sedated with
intramuscular midazolam (0.2 mg/kg), and arterial
oxygen saturation (SpO2) was monitored (Nonin
Medical, Plymouth, MN, USA). Isoflurane anaesthe-
sia (4% v/v; Abbott Laboratories, Maidenhead,
Berkshire, UK) was initially given through a
facemask to facilitate tracheostomy and intubation
and was used for maintenance anaesthesia (3%
during surgery and 2% otherwise). Piglets were
mechanically ventilated; ventilator settings were
adjusted to maintain partial pressure of oxygen
(PaO2) and carbon dioxide (PaCO2) at 8–13 kPa and
4.5–6.5 kPa, respectively, allowing for temperature
and fraction of inspired oxygen (FiO2) correction of
the arterial blood sample.
A double-lumen umbilical venous catheter
(Vigon, Ecouen, France) was inserted for infusion of
maintenance fluids (10% dextrose, 60 ml/kg/day
before insult and 40 ml/kg/day after resuscitation),
fentanyl (3–6 μg/kg/h; Mercury Farmer, Berlin,
Germany), and antibiotics [benzylpenicillin
(Genus Pharmaceutical, Newbury, Berkshire, UK)
50 mg kg, every 12 h and gentamicin (Patheon,
Swindon, Wiltshire, UK) 4 mg/kg, once a day]
through one lumen and the other lumen was kept
for dexmedetomidine infusion only. An umbilical
arterial catheter (Vigon) was inserted for continuous
monitoring of heart rate and arterial blood pressure,
and intermittent blood sampling was used to
measure plasma dexmedetomidine concentrations,
PaO2, PaCO2, pH, electrolytes, glucose and lactate
(data not shown, Abbot Laboratories). Bolus infu-
sions of 0.9% saline (Baxter, Thetford, Norfolk, UK;
10 ml/kg), dopamine and dobutamine (5–20 μg/
kg/min), adrenaline (0.1–1.5 μg/kg/min) and
noradrenaline (0.02–1 μg/kg/min) maintained
mean arterial blood pressure above 40 mmHg. All
animals received continuous physiological monitor-
ing (SA Instruments Inc, Stony Brook, NY, USA) and
intensive life support throughout the study. Arterial
lines were maintained by infusing 0.9% saline solu-
tion (Baxter; 0.3 ml/h); heparin sodium was added
at a concentration of 0.5 IU/ml to prevent line
blockage.
Both common carotid arteries were surgically iso-
lated at the level of the fourth cervical vertebra and
encircled by remotely controlled vascular occluders
(OC2A, In Vivo Metric, Healdsburg, CA, USA).
After surgery, piglets were positioned prone in a
plastic pod, and the head was immobilised securely
below the magnetic resonance spectroscopy (MRS)
surface coil on each side.
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Cerebral hypoxia-ischaemia
In the MRS system, transient hypoxia-ischaemia
was induced by remote occlusion of both common
carotid arteries, using inflatable vascular occluders
and also reducing FiO2 to 0.09. During transient
hypoxia-ischaemia, cerebral energetic changes were
monitored every 2 min by phosphorus-31 (31P) MRS
and the β-nucleotide triphosphate (NTP; mainly
ATP) peak height was automatically quantified.
Once the β-NTP peak height had fallen to 40% of
baseline, titration began by adjusting FiO2 to main-
tain the β-NTP peak height at 35% (30–40%) of
baseline value for 12.5 min. At the end of this 12.5-
min period, the animal was resuscitated by deflating
the occluders and increasing FiO2 to 0.21. 31P
magnetic resonance spectra were acquired for a
further 1 h to follow recovery after resuscitation.
Acute energy depletion (AED) was calculated by the
time integral of the change in β-NTP peak area
relative to the exchangeable phosphate pool [EPP;
EPP = inorganic phosphate (Pi) + phosphocreatine
(PCr) + (2γ + β) − nucleotide triphosphate (NTP)]
during hypoxia-ischaemia and the first 60 min after
resuscitation as described previously.30
Experimental groups
Before transient hypoxia-ischaemia, baseline data
were acquired after stabilisation of the animal in the
MRS system. After resuscitation, piglets were
administered dexmedetomidine in combination
with hypothermia. Fentanyl infusion was stopped
following dexmedetomidine bolus and was substi-
tuted by dexmedetomidine infusion. Whole body
cooling was achieved in less than 90 min using
a water mattress and maintained for a total of
18–24 h at target rectal temperature of 33.5°C.
Dexmedetomidine was administered with a loading
dose of 1 μg/kg over 20 min and then infused for
46–48 h at the following doses: i) 10 μg/kg/h
started at 4 h after hypoxic ischemic insult (HI),
n = 1; ii) 2–10 μg/kg/h variable dose started with
2 μg/kg/h at 4 h with increments of 2 μg/kg/h 4
hourly, n = 1; iii) 1.5 μg/kg/h started at 4 h after
hypoxia-ichaemia, n = 1; iv) 1.5 μg/kg/h started at
30 min post hypoxia-ischaemia, n = 3; v) 0.8 μg/
kg/h started at 30 min post hypoxia-ischaemia,
n = 1; vi) 0.6 μg/kg/h started at 30 min post
hypoxia-ischaemia, n = 2; vii) 1.5 μg/kg/h as
control with no hypoxia-ischaemia, n = 1. Piglets
were cooled: group i, ii and iii had cooling from
2–26 h post HI while group iv, v and vi had cooling
from 4–22 h post hypoxia-ischaemia (Table 1).
Group vii was not cooled. A solution of 4 μg/ml
dexmedetomidine was made by adding 200 μg
(2 ml) dexmedetomidine to 48 ml 10% glucose and
used for infusion.
At the end of hypothermic treatment, piglets were
re-warmed at rate of 0.5°C/h to normothermia
(38.5°C for a piglet). Blood for dexmedetomidine PK
assay was sampled at baseline (pre-insult), 0.5, 1, 2,
6, 9, 12, 24 and 48 h post-insult. Blood for chemistry
and blood gas analysis was taken at baseline and
then every 6 h post hypoxic ischaemic insult (data
not shown).
PK analysis
Population parameter estimations. A one-
compartment linear disposition model was used to
fit data to the PK model. Population parameter esti-
mates were obtained using non-linear mixed effects
modelling (NONMEM VII, Globomax LLC,
Hanover, MD, USA).31 This model accounts for
population parameter variability (between subjects)
and residual variability (random effects) as well as
parameter differences predicted by covariates (fixed
effects). The population parameter variability in
model parameters was modelled by a proportional
variance model. An additive error (ERRADD) and a
proportional term error term (ERRPROP) were used to
characterise the residual unknown variability. The
Table 1
Summary of the dexmedetomidine maintenance dose, start time and cooling periods in relation to the hypoxic-ischaemic insult.
Dexmedetomidine maintenance
dose (μg/kg/h)
Start time of dexmedetomidine dose Cooling period Number
(n)(h after hypoxia-ischaemia) (h after hypoxia-ischaemia)
10 4 2–26 1
2–10 4 2–26 1
1.5 4 2–26 1
1.5 0.5 4–22 3
0.8 0.5 4–22 1
0.6 0.5 4–22 2
1.5 – No cooling 1
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variance of the residual unidentified variability,
ηRUV,i, was estimated.32 The population mean param-
eters, between subject variance and residual vari-
ance were estimated using the first-order
conditional interaction estimate method using
ADVAN1 TRANS2. Convergence criterion was
three significant digits. A Compaq Digital Fortran
Version 6.6A compiler with Intel Celeron 333 MHz
CPU (Intel Corp., Santa Clara, CA, USA) under MS
Windows XP (Microsoft Corp., Seattle, WA, USA)
was used to compile NONMEM. The population
parameter variability is modelled in terms of
random-effect (η) variables. Each of these variables
is assumed to have mean 0 and a variance denoted
by ω,2 which is estimated. The covariance between
two elements of η [e.g., clearance (CL) and volume
of distribution (V)] is a measure of statistical asso-
ciation between these two variables. Their covari-





×( )ω ω2 2
The covariance of clearance and distribution volume
variability was incorporated into the model.
Covariate analysis. The parameter values were
standardised for a body weight of 70 kg using an
allometric model33,34
P P W Wi std i std
PWR
= × ( )
where Pi is the parameter in the ith individual, Wi is
the weight in the ith individual and Pstd is the
parameter in a pig with a weight Wstd of 70 kg. This
standardisation allows comparison of piglet
parameter estimates with those reported for adults.
The PWR exponent was 0.75 for clearance, 0.25 for
half times and 1 for distribution volumes.34
CL CLstd
Wt
L hi = ×
⎛⎝ ⎞⎠70
0 75.
Covariate analysis included a model investigating
the impact of temperature on clearance:
Effect Ftemp TEMP L hTEMP = + × −( )1 37
where CLstd is the population estimates for CL,
standardised to a 70 kg pig using allometric models,
and Ftemp is a constant. Piglets also suffered an
episode of AED, where they sustained ischemic
brain injury similar to perinatal asphyxia. An
additional scaling factor [hypoxia-ischaemia
severity or acute energy depletion factor (FAED)]
was applied to clearance at that time
CL CLstd
Wt
Effect FAED L hi TEMP= ×
⎛⎝ ⎞⎠ × ×70
0 75.
Quality of fit. The quality of fit of the PK model to
the data was sought by NONMEM’s objective func-
tion and by visual examination of plots of observed
vs. predicted concentrations. Models were nested
and an improvement in the objective function was
referred to the chi-square distribution to assess sig-
nificance, e.g., an objective function change (ΔOBJ)
of 3.84 is significant at α = 0.05.
Bootstrap methods, incorporated within the
Wings for NONMEMprogram, provided ameans to
evaluate parameter uncertainty.35 A total of 1000 rep-
lications were used to estimate parameter confi-
dence intervals. A visual predictive check (VPC),36 a
modelling tool that estimates the concentration pre-
diction intervals and graphically superimposes
these intervals on observed concentrations after a
standardised dose, was used to evaluate how well
the model predicted the distribution of observed
dexmedetomidine concentrations. Simulation was
performed using 1000 subjects with characteristics
taken from 10 studied piglets; these simulations
were generated by randomly using values from the
estimated parameters and their variability. This is an
advanced internal method of evaluation37,38 and is
considered better than the commonly used plots of
observed vs. predicted values.39 For data such as
these where covariates such as dose, weight and
height are different for each piglet, we used a pre-
diction corrected VPC (PC-VPC).40 Observations
and simulations are multiplied by the population
baseline value divided by the individual-estimated
baseline.
Results
Piglets had a mean age of 22.9 h [standard deviation
(SD) 1.2 h] and weight 1.76 kg (SD 0.23 kg). The PK
analysis included data from 10 piglets that showed
substantial variation in plasma concentrations
over the 48 h study period (Fig. 1). Plasma
dexmedetomidine concentrations were above the
safe sedative level in human neonates (0.4–0.8 1 μg/
ml) in all but one piglet. Analysis suggested that a
two-compartment model was not superior to a one-
compartment model (ΔOBJ 5.560 despite two addi-
tional parameters required for the two-compartment
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model). Population parameter estimates (between-
subject variability) were CL 3.52 l/h 70 kg [coeffi-
cient of variation (CV) 46.6%] and V 235 l 70/kg
(109.1%). The correlation of between-subject variabil-
ity for CL and V was −0.756. Temperature reduced
clearance (ΔOBJ 3.86); CL was reduced 32.7% at a
temperature of 33.5°C. The hypoxic-ischaemic insult
had further impact (ΔOBJ 11.15), reducing CL by
55.8%. These parameter estimates are shown in
Table 2. The satisfactory PC-VPC plot for these PK
data is shown in Fig. 2. From these analyses, we
propose that dexmedetomidine 2 μg/kg followed by
an infusion of 0.028 μg/kg/h when combined with
hypothermia following hypoxic-ischaemic brain
injury will provide a dexmedetomidine concentra-
tion of 0.5–0.6 μg/l.
Haemodynamic instability was noted in piglets
over study period with episodes of bradycardia,
hypotension and hypertension (Table 3). Seven out
of the nine piglets who received a hypoxic-
ischaemic insult experienced cardiac arrest. All
haemodynamic adverse events occurred in piglets
with plasma concentrations greater than 1 μg/l.
Discussion
PK modelling in this piglet perinatal asphyxia
model demonstrated that dexmedetomi-
dine plasma concentrations are influenced by both
hypothermia and a preceding hypoxic-ischaemic
insult. All dexmedetomidine infusion regimens led
to plasma concentrations above those associated
with sedation in neonates and children (0.4–0.8 μg/
l). Adverse cardiovascular events occurred in seven
out of nine piglets receiving a dexmedetomidine
infusion following hypoxia-ischaemia and thera-
peutic hypothermia. All haemodynamic adverse
events occurred in piglets with plasma concentra-
tions greater than 1 μg/l. These adverse cardiovas-
cular events consisted of episodes of hypotension,
bradycardia, hypertension and cardiac arrest; the
events occurred at high drug concentrations due to
much lower dexmedetomidine clearance than ini-
tially hypothesised. Further studies are needed in
neonatal animal models to provide information
on the safe dexmedetomidine dose for future
neuroprotection studies.
Our initial dose was based on a previous study of
adult pigs in which an infusion of 20 mcg/kg/h was
administered with no adverse haemodynamic
effects.41 As we knew that the clearance estimates of
dexmedetomidine in neonates are 50% lower than
adult values,24 we started with a dexmedetomidine
infusion rate that was 50% lower. However, our data
suggest that clearance estimates in neonatal piglets
following hypoxia-ischaemia and during therapeu-
tic hypothermia are approximately 10% those
reported for clearance in adult humans (CL) 42.1 l/h
70/kg (CV 30.9%).24
In children in intensive care, a plasma concentra-
tion of 0.4–0.8 μg/lwas associatedwith safe sedation
(using simulation of published infusion rates).24 This
is similar to the suggested effective sedative adult
plasma concentration range of dexmedeto-
midine of 0.6–1.25 μg/l. All piglet dexmedetomi-
dine concentrations were higher than 1.0 μg/l. Drug
accumulation, attributable to both apoor initial clear-
ance estimate in piglets, and further reduction due to
the effects of cooling and preceding hypoxia-
ischaemia over the 48 h study period, was associated
with cardiovascular problems including bradycar-
Fig. 1. Dexmedetomidine plasma concentrations from nine piglets
at varying infusion rates following hypoxic-ischaemic brain injury
and co-administration with hypothermia. One additional piglet did
not incur brain injury and did not undergo hypothermia. The safe
sedative concentration in human neonates is 0.4–0.8 μg/ml; the
dotted line is at 1 μg/ml. All piglets achieved dexmedetomidine
concentrations above 1 μg/ml.
Table 2
Standardised population pharmacokinetic parameter estimates.
Parameter Estimate %BSV 95%CI
CLstd (l/h/70 kg) 3.52 46.6 1.35, 9.01
Vstd (l/70 kg) 236 191 85.8, 497
Ftemp 0.0934 – 0.0127, 0.244
FEAD 0.558 2.6 0.329, 1.21
ErrADD (mcg/l) 0.171 ηRUV
0.643
0.0356, 0.657
ErrPROP (%) 26 4.5, 48.9
BSV is the between-subject variability, CI is the confidence inter-
val of the structural estimate; CLstd is the standardised clear-
ance; Vstd is the standardised volume; additive and proportional
error term respectively are ErrADD and ErrPROP.
FAED - acute energy depletion factor.
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dia, hypotension and hypertension, culminating in
cardiac arrest in seven piglets (Table 3). Bradycardia
and hypotension are likely to have resulted from
central α2A-adrenergic receptors causing sympa-
tholysis.6 Bradycardiamay be a particular problem in
the neonate due to the heart’s relatively fixed stroke
volume. In contrast, stimulation of peripheral post-
synapticα2B-adrenergic receptors, andα1-adrenergic
receptors, may be responsible for the pressor effect
and hypertension.6 While dexmedetomidine shows
1200-fold selectivity forα2- overα1-adrenergic recep-
tors, the high concentrations of dexmedetomidine
achieved in our study suggest that α1- or α2B-
adrenergic receptors may have contributed to the
cardiovascular changes observed.
The findings that both hypoxia and hypothermia
reduce dexmedetomidine clearance have important
implications to the use of dexmedetomidine in
babies with neonatal encephalopathy undergoing
cooling. In two children with traumatic head injury
undergoing therapeutic hypothermia, clinically sig-
nificant bradycardia developed with dexmedetomi-
dine; however, plasma concentrations were not
measured.42 In adults, the majority (85%) of
dexmedetomidine is metabolised in the liver by
direct glucuronidation [5-diphosphoglucuronosyl
transferase (UGT1A4andUGT2B10)] and15%by the
cytochrome P450 enzymes (CYP450).28 Following
perinatal hypoxia-ischaemia, multi-organ failure
occurs in some infants, which may include liver dys-
function anddecreased cardiac output;43 both factors
can reduce dexmedetomidine clearance. CYP450
enzymes are known to be affected by hypothermia;
drugs used in neonatal intensive care such as
midazolam, fentanyl, propofol, vecuronium,
phenobaribitol and propranolol all have reduced
clearance.29,44 Hypothermia is thought to change the
binding pocket confirmation of the CYP450, reduce
the substrate affinity for the CYP450 binding sites
and slow the rate of redox reactions performed by
CYP450 enzymes.44 The uridine 5-diphosphoglu-
curonosyl transferase (UGT) activity has also been
seen to be reduced with hypothermia in brain-
injured adult patients.45
There are limitations to this study. Our sample size
was limited because of the need to minimise the
number of animals used for ethical reasons. The data
show large variability of parameter estimates;
however, future studies are planned with larger
numbers and more intense sampling with and
without hypothermia or hypoxia-ischaemia. The
hepatic clearance is likely to be even more impaired
in severe asphyxia than in our piglet hypoxia-
ischaemia model (our model induces systemic
hypoxia and localised cerebral ischaemia). There-
fore, the hepatic hypoxia experienced in our model
may be less compared with infants with severe
multi-organ failure associated with neonatal
encephalopathy.
Our data highlight the importance of understand-
ing the pharmacokinetics of dexmedetomidine for
future pre-clinical neuroprotection trials. Sato et al.
saw no augmentation of hypothermic neuroprotec-
tion with dexmedetomidine in an adult incomplete
cerebral ischaemia rodent model; however, plasma
concentrations of dexmedetomidine were not meas-
ured.46 A biphasic neuroprotective response to low-
and high-dose clonidine (another α2-adrenergic
receptor agonist) was observed in a pre-term fetal
sheep study: low-dose clonidine demonstrated a
neuroprotective effect whereas high-dose clonidine
was associated with hyperglycaemia, more frequent
delayed seizures and loss of neuroprotection.47
It is vital that further studies relate plasma
dexmedetomidine levels with brain protection to
ascertain whether sedative or sub sedative doses are
protective. Our PK analysis in a piglet perinatal
asphyxia model with therapeutic hypothermia sug-
gests that dexmedetomidine clearance in the piglet is
affected by both temperature and prior hypoxic-
Fig. 2. Visual predictive check for the
dexmedetomidine pharmacokinetic (PK)
model. All plots show median and 90%
intervals (solid and dashed lines). Left hand
plot shows all prediction corrected observed
concentrations. Right hand plot shows pre-
diction corrected percentiles (10%, 50%,
90%) for observations (lines with symbols)
and predictions (lines) with 95% confidence
intervals for prediction percentiles (gray
shaded areas).
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Table 3
Dexmedetomidine infusion rates and plasma concentrations for each piglet. The timing of the hypothermia (cooling to 33.5°C; HT),
normothermia (NT) and rewarming (RW) phases are shown. The timing of the cardiac arrest and resuscitation are shown for those
subjects with these events. The oxygen saturation (O2 sats), heart rate (HR) and mean arterial blood pressure (MABP) for time points
corresponding to when dexmedetomidine plasma levels were taken are shown. (BL: baseline)
Piglet DEX dose
μg/kg/h
Time DEX plasma level
(μg/ml)
Temp Arrests? O2 Sats % HR Beat/min MABP
Study 1
1-1 0 BL – NT 98 136 37
1-2 0 0.5 h – NT 98 140 55
1-3 0 1 h – NT 97 147 56
1-4 1.5 6 h – HT 98 98 54
1-5 1.5 9 h 3.412 HT 98 90 46
1-6 1.5 12 h 4.473 HT 98 98 47
1-7 1.5 24 h 6.916 RW Fatal arrest 100 94 37
Study 2
2-1 0 BL – NT 98 133 45
2-2 1.5 0.5 h 1.047 NT 98 132 51
2-3 1.5 1 h 1.226 NT 97 136 49
2-4 1.5 2 h 1.713 NT 97 135 46
2-5 1.5 6 h 3.191 NT 95 137 52
2-6 1.5 9 h 3.855 NT 98 145 50
2-7 1.5 12 h 5.141 NT 99 147 51
2-8 1.5 24 h 8.052 NT 98 149 49
2-9 1.5 48 h 8.115 NT 97 135 56
Study 3
3-1 0 BL – NT 99 154 42
3-2 1.5 0.5 h – NT 96 166 53
3-3 1.5 1 h 2.179 NT 99 130 46
3-4 1.5 2 h 2.636 NT 99 131 48
3-5 1.5 6 h 3.809 HT 99 95 47
3-6 1.5 9 h 4.307 HT 98 92 41
3-7 1.5 12 h 6.660 HT 99 88 33
3-8 1.5 24 h 13.511 RW 99 164 43
3-9 1.5 48 h 5.877 NT 99 189 44
Study 4
4-1 0 BL – NT 98 154 41
4-2 1.5 0.5 h 1.869 NT 98 141 46
4-3 1.5 1 h 1.685 NT 98 140 45
4-4 1.5 2 h 3.076 NT 98 134 46
4-5 1.5 6 h 4.563 HT 99 93 45
4-6 1.5 9 h 6.656 HT 99 84 46
4-7 1.5 12 h 7.763 HT 100 95 45
4-8 1.5 24 h 9.067 RW 97 131 35
4-9 1.5 48 h 7.470 NT 98 127 49
Study 5
5-1 0 BL – NT 99 175 51
5-2 1.5 0.5 h – NT 99 187 50
5-3 1.5 2 h – NT 94 169 51
5-4 1.5 6 h 0.929 HT 100 111 48
5-5 1.5 9 h 2.449 HT 100 115 50
5-6 1.5 12 h 3.579 HT 100 153 45
5-7 1.5 18 h 7.065 HT 98 117 48
5-8 1.5 24 h 8.954 RW 98 105 33
5-9 1.5 30 h – NT 99 143 48
5-10 1.5 40 h 11.886 NT 80 146 34
5-11 1.5 48 h 6.506 NT Fatal arrest 80 146 34
Study 6
6-1 0 BL – NT 94 125 44
6-2 0 0.5 h – NT 91 111 37
6-3 0.8 1 h 0.930 NT 94 100 58
6-4 0.8 6 h 1.400 HT 97 135 60
6-5 0.8 12 h 2.201 HT 96 103 50
6-6 0.8 16 h 5.767 HT 98 173 28
6-7 0.8 24 h 27.519 RW Arrest-resuscitated 98 181 34
6-8 0.8 30 h 1.620 NT 96 178 55
6-9 0.8 36 h 2.131 NT 97 160 78
6-10 0.8 48 h 1.772 NT 97 107 54
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ischaemic brain injury. Dexmedetomidine clearance
may be reduced almost tenfold in the newborn fol-
lowing hypoxic-ischaemic brain injury with subse-
quent therapeutic hypothermia. From our one-
compartment model, we estimate that a bolus of
2 μg/kg dexmedetomidine over 20 min followed
by an infusion of 0.028 μg/kg/h dexmede-
tomidine during therapeutic hypothermia will
achieve a plasma concentration of 0.5–0.6 μg/l (con-
centration associated with sedation in human new-
borns); this may be a suitable dose to use in pre-
clinical studies assessing possible neuroprotective
effects of dexmedetomidine following hypoxia-
ischaemia. Further PK studies are vital in pre-clinical
and clinical neuroprotection studies of
dexmedetomidine.
In summary, this PK study in a piglet perinatal
asphyxia model demonstrated adverse cardiovascu-
lar effects of dexmedetomidine; these cardiovascular
events were associated with unexpectedly high
dexmedetomiidne plasma levels secondary to
reduced clearance due to cumulative effects of
both hypothermia and exposure to hypoxia.
Dexmedetomidine clearancemay be further reduced
in severe asphyxia with multi-organ failure.
Dexmedetomidine clearance was reduced almost
ten-fold in this neonatal asphyxia model compared
with adult values, emphasising the critical impor-
tance of careful PK studies in the newborn.
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(μg/ml)
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Study 7
7-1 0 BL – NT 94 155 35
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7-5 0.6 6 h 0.082 HT 98 154 53
7-6 0.6 9 h 0.096 HT 99 145 72
7-7 0.6 12 h 0.221 HT 98 161 64
7-8 0.6 18 h 0.353 HT 98 125 59
7-9 0.6 24 h 1.041 RW Fatal arrest 99 169 65
Study 8
8-1 0 BL – NT 88 235 45
8-2 0.6 0.5 h – NT 90 202 43
8-3 0.6 1 h – NT 94 189 35
8-4 0.6 2 h – NT 95 185 36
8-5 0.6 6 h – HT 97 178 51
8-6 0.6 9 h 0.276 HT 98 158 43
8-7 0.6 12 h 1.301 HT 98 151 44
8-8 0.6 24 h 3.190 RW Fatal arrest 50 15
Study 9
9-1 0 BL – NT 100 160 58
9-2 0 0.5 h – NT 99 144 61
9-3 10 6 h 8.736 HT 98 181 49
9-4 10 12 h 32.551 HT 99 141 41
9-5 10 26 h 27.614 RW 175 33
9-6 10 30 h 23.353 NT 95 173 35
9-7 10 36 h 29.608 NT Fatal arrest 98 170 35
Study 10
10-1 0 BL – NT 92 160 61
10-2 0 0.5 h – NT 98 167 51
10-3 0 2 h – NT 100 158 46
10-4 2 6 h 0.614 HT 99 92 38
10-5 6 12 h 2.489 HT 100 104 54
10-6 8 18 h 9.649 HT 99 124 40
10-7 10 24 h 18.369 HT Arrest-resuscitated 99 126 58
10-8 10 36 h 39.020 NT 95 185 42
10-9 10 48 h 44.115 NT 96 93 56
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